Johnson and Johnson COVID-19 Vaccine

FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

Janssen COVID-19 Vaccine Standing Orders for Administering Vaccine

Janssen COVID-19 Vaccine (Johnson & Johnson) Vaccine Preparation and Administration Summary

J & J COVID-19 vaccine expiration date extension

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021

FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review

Thrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia)

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine 4-13-21

FDA Media Briefing: Janssen COVID-19 Vaccine 4-13-21

Vaccine Announcement 

Vaccine EUA Product Information

Vaccine EUA Fact Sheet for Recipients and Caregivers

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine

Understanding Viral Vector COVID-19 Vaccines

Selected Adverse Events Reported after COVID-19 Vaccination